NEW YORK, Jan. 12 (GenomeWeb News) - Clinical Data will collaborate with the University of Pittsburgh Cancer Institute on a metabolomics study of lung cancer patients, the company said today.
Under the agreement, Clinical Data will apply metabolomics analysis to serum samples from a population of patients diagnosed with lung cancer and matched controls without lung cancer. UPCI will provide the serum samples.
Any new intellectual property or inventions from this study will remain the property of the discovering party, Clinical Data said. Both parties retain the rights to publish the results and disseminate information pertaining to the research conducted under the agreement.
The study is part of the National Caner Institute's Specialized Program of Research Excellence in Lung Cancer at UPCI.